CD30

This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. It is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported. == Clinical significance ==

CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus a useful marker in distinguishing between these germ cell tumors. CD30 and CD15 are also expressed on Reed-Sternberg cells typical for Hodgkin's lymphoma. == Cancer treatment ==

CD30 is the target of the FDA approved therapeutic brentuximab vedotin (Adcetris). It is approved for use in: • Hodgkin lymphoma (HL) (brentuximab vedotin) after failure of autologous stem cell transplant (ASCT) • HL in patients who are not ASCT candidates after failure of at least 2 multiagent chemotherapy regimens • Systemic anaplastic large cell lymphoma (sALCL) after failure of at least 1 multiagent chemotherapy regimen • Primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy • Various types of CD30-positive T cell lymphomas Brentuximab vedotin is also currently being studied in and recommended for treating: • Various types of CD30-positive B cell lymphomas • CD30-positive cases of the NK cell lymphoma, extranodal NK/T-cell lymphoma, nasal type == Interactions ==

CD30 has been shown to interact with TRAF5, and TRAF2. == References ==